Exact sciences corporation stock.
Oncotype DX ® Test Recognized as the 'Preferred' and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer. Update based on first results from the independent RxPONDER study presented at the 2020 San Antonio Breast Cancer Symposium 1. Madison, Wis., March 31, 2021 - Exact Sciences today …
Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ...Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Dec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... Exact Sciences exited third-quarter 2021 with cash and cash equivalents, and marketable securities of $1.22 billion compared with $1.31 billion at the end of second-quarter 2021.MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical Oncology (ESMO) Congress, October 20-24, in Madrid, Spain.
On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.
Innovation One, the headquarters of Exact Sciences in Madison, Wisconsin (2020). ; Innovation One, the headquarters of Exact Sciences in Madison, Wisconsin (2020) ...On July 24, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $93.84 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 0.09%, and its shares gained 105.65% ...
Dec 4, 2023 · Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the ... MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.02-Nov-2023 ... On today's stock market, EXAS stock sank 1.7% to 62.46. Is EXAS Stock Nearing Profitability? Overall, Exact Sciences posted no earnings on ...Exact Sciences Corporation‘s EXAS shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the said time frame. The company has a ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...
30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ...
Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA …
Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.Exact Sciences Corp. announced the launch of the OncoExTra therapy selection test in the United States. OncoExTra is a next-generation sequencing (NGS), comprehensive DNA and RNA based genomic test providing doctors and their patients a complete molecular picture of the patient's cancer.intraday 1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Wednesday 11/29/2023 the closing price of the EXACT …Exact Sciences Corporation's (EXAS) CEO Kevin Conroy on Q4 2020 Results - Earnings Call Transcript SA Transcripts Tue, Feb. 16, 2021 Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q3 2020 ...Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...MADISON, Wis., Nov. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and …MADISON - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $628.3 million for the third quarter ended September 30, 2023, compared to $523.1 million for the same period of 2022. ' Exact Sciences' third-quarter results reflect …
Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...
"Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ...Nov 30, 2023 · 30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ... According to 15 stock analysts, the average 12-month stock price forecast for Exact Sciences stock is $92.07, which predicts an increase of 39.52%. The lowest target is $73 and the highest is $130. On average, analysts rate Exact Sciences stock as a strong buy.View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Jul 19, 2023 · Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ... MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, and …Analyst Report: Exact Sciences Corporation Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and ... Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ... 15-May-2017 ... One week after hitting an all-time high, Exact Sciences Corp. stock slipped as much as 8 percent in early trading Monday after a well-known ...Exact Sciences Corp. announced the launch of the OncoExTra therapy selection test in the United States. OncoExTra is a next-generation sequencing (NGS), comprehensive DNA and RNA based genomic test providing doctors and their patients a complete molecular picture of the patient's cancer.
Nov 17, 2023 · Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and commercializes diagnostic tests for cancer and other diseases. See real-time data, market cap, key data and news of EXAS on Nasdaq.
Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...
Dec 1, 2023 · Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ... Nov 17, 2023 · Get the latest Exact Sciences Corporation (EXAS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...10-Apr-2023 ... MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic ...MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Story continues. SANTA CLARA, Calif. & MADISON, Wis., September 12, 2023--Agilent Technologies, Inc. (NYSE: A) and Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and ...Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently down 3.17% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $59.51. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $39.90. Year to date, Exact ...EXAS Exact Sciences Corporation Stock Price & Overview 34.09K followers $67.03 3.03 ( +4.73%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $67.10 +0.07 (+0.10%) 7:58 PM Summary Ratings...
Exact Sciences Announces Fourth Quarter 2022 Results Reports record revenue, expects revenue of $2,265-2,315 million and positive adjusted EBITDA for full year 2023 02-21 - 1 view. CONSULTING AGREEMENT 02-21. EXACT SCIENCES CORPORATION EQUITY AWARD DEATH, DISABILITY AND RETIREMENT POLICY …Under the terms of the agreement, for each share of Genomic Health common stock they own, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock ...29-Jul-2019 ... ... share in a cash and stock transaction valued at $2.8 billion. The ... Corporation, 441 Charmany Drive, Madison, Wisconsin 53719, or by ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...Instagram:https://instagram. spectairethe sphere las vegas capacityvanguard fixed incomebest performing reits last 10 years Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, … spy pricesembroker reviews Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ... self storage etf Buy candidate since Nov 17, 2023 Loss -1.39% PDF. The EXACT Sciences Corporation stock price gained 0.368% on the last trading day (Wednesday, 22nd Nov 2023), rising from $65.14 to $65.38. During the last trading day the stock fluctuated 3.02% from a day low at $64.84 to a day high of $66.80. The price has been going up and down for this period ...Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to ... EXACT Sciences Corp. Aktie Profil. Die EXACT Sciences Corp. Aktie wird unter der ISIN US30063P1057 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, Hannover, NASDAQ, Moskau ...